A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062)

Inclusion Criteria: * negative clinical history of measles, mumps, rubella, varicella, and zoster Exclusion Criteria: * received any measles, mumps, rubella, or varicella vaccine at any time prior to the study, or is anticipated to receive any of these vaccines outside the study * any congenital or acquired immune deficiency, neoplastic disease, or depressed immunity * received systemic immunomodulatory steroids within 3 months prior to entering the study or is expected to require them throughout the study * history of allergy or anaphylactoid reaction to neomycin, gelatin, sorbital, egg proteins, chicken proteins, or any components of M-M-R™ II or VARIVAX™ * received salicylates within 14 days prior to study vaccination * exposed to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to study vaccination * received any non-live vaccine within 14 days prior to any study vaccination or is expected to received such vaccine during the 42-day period after each study vaccination * received any live vaccine within 30 days prior to any study vaccination or is expected to received such vaccine during the 42-day period after each study vaccination * received immune globulin, a blood transfusion, or blood-derived products within 5 months prior to any study vaccination * fever illness (≥102.2°F \[39.0°C\]) within 72 hours prior to study vaccination * born to a human immunodeficiency virus (HIV)-infected mother * participated in any other clinical trial (other than a surveillance study) within 30 days prior to study enrollment